{
    "eid": "2-s2.0-85149130394",
    "title": "Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac",
    "cover-date": "2023-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "adverse events",
        "BNT162b2",
        "booster COVID-19 vaccine",
        "cancer patients",
        "ChAdOx1",
        "CoronaVac",
        "malignancy",
        "mRNA-1273",
        "safety"
    ],
    "authors": [
        "Passakorn Wanchaijiraboon",
        "Panot Sainamthip",
        "Nattaya Teeyapun",
        "Sutima Luangdilok",
        "Yong Poovorawan",
        "Nasamon Wanlapakorn",
        "Suebpong Tanasanvimon",
        "Virote Sriuranpong",
        "Thiti Susiriwatananont",
        "Nicha Zungsontiporn",
        "Nussara Pakvisal"
    ],
    "citedby-count": 0,
    "ref-count": 34,
    "ref-list": [
        "Effects of cancer on patients with COVID-19: A systematic review and meta-analysis of 63,019 participants",
        "Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study",
        "Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China",
        "Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data",
        "SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness",
        "SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses",
        "Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months",
        "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar",
        "Waning Immunity after the BNT162b2 Vaccine in Israel",
        "COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant",
        "Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: Test negative case-control study",
        "Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar",
        "Relative Vaccine SARS-CoV-2 RNA Vaccine Booster Dose Against the Omicron Variant",
        "BNT162b2 Vaccine Booster and Mortality Due to COVID-19",
        "Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: A prospective cohort study",
        "Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer",
        "Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older",
        "Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine",
        "Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort Study",
        "Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study",
        "Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial",
        "Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination",
        "Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: A survey among health care workers",
        "COVID-19 vaccine reactogenicity\u2014A cohort event monitoring study in the Netherlands using patient reported outcomes",
        "Unilateral axillary Adenopathy in the setting of COVID-19 vaccine",
        "Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties",
        "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine",
        "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine",
        "Lymphadenopathy after the Third COVID-19 Vaccine",
        "COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience",
        "Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) COVID-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chantaburi",
            "@id": "128297194",
            "affilname": "Phrapokklao Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128297194",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Covid vaccine antibody research fund",
        "Phrapokklao Hospital",
        "Ratchadapiseksompotch Fund",
        "Thai Red Cross Society",
        "King Chulalongkorn Memorial Hospital",
        "National Research Council",
        "NRCT",
        "Faculty of Medicine, Chulalongkorn University",
        "Health Systems Research Institute"
    ]
}